Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

NCT04646837 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Albumin Paclitaxel
DRUG: Carboplatin/Cisplatin

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]